TRAIL induces apoptosis in cancer cells whilst sparing normal tissues. Despite promising preclinical results, few patients responded to treatment with recombinant TRAIL (Apo2L/ Dulanermin) or TRAIL-R2-specific antibodies, such as conatumumab (AMG655). It is unknown whether this was due to intrinsic TRAIL resistance within primary human cancers or insufficient agonistic activity of the TRAIL-R-targeting drugs. FcγR-mediated crosslinking increases the cancer-cell-killing activity of TRAIL-R2-specific antibodies in vivo. We tested this phenomenon using FcγR-expressing immune cells from patients with ovarian cancer. However, even in the presence of high numbers of FcγR-expressing immune cells, as found in ovarian cancer ascites, AMG655-induced apoptosis was not enabled to any significant degree, indicating that this concept may not translate into clinical use. On the basis of these results we next set out to determine whether AMG655 possibly interferes with apoptosis induction by endogenous TRAIL which could be expressed by immune cells. To do so, we tested how AMG655 affected apoptosis induction by recombinant TRAIL. This, however, resulted in the surprising discovery of a striking synergy between AMG655 and non-tagged TRAIL (Apo2L/TRAIL) in killing cancer cells. This combination was as effective in killing cancer cells as highly active recombinant isoleucinezipper-tagged TRAIL (iz-TRAIL). The increased killing efficiency was due to enhanced formation of the TRAIL death-inducing signalling complex (DISC), enabled by concomitant binding of Apo2L/TRAIL and AMG655 to TRAIL-R2. The synergy of AMG655 with Apo2L/TRAIL extended to primary ovarian cancer cells and was further enhanced by combination with the Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the proteasome inhibitor bortezomib or a SMAC mimetic. Importantly, primary human hepatocytes were not killed by the AMG655-Apo2L/TRAIL combination, also not when further combined with bortezomib or a SMAC mimetic. We therefore propose that clinical-grade non-tagged recombinant forms of TRAIL, such as dulanermin, could be combined with antibodies such as AMG655 to introduce a highly active TRAIL-R2-agonistic therapy into the cancer clinic.
Introduction
TNF-related apoptosis-inducing ligand (TRAIL) can kill tumour cells in vivo without harming normal tissues (1, 2), a finding that initiated the clinical development of TRAILreceptor (TRAIL-R) agonists. Current TRAIL-R-agonistic drugs were developed during a period of concern about their potential hepatotoxicity (3) . Hence, in comparison to highly active recombinant forms of TRAIL such as leucine-zipper-(1) or isoleucine-zipper-tagged TRAIL (LZ-TRAIL or iz-TRAIL) (4), the clinically used recombinant non-tagged TRAIL form, dulanermin (5) , is a relatively weak agonist of TRAIL-R1 (also known as DR4) and TRAIL-R2 (also known as DR5, Apo2, KILLER, TRICK2), the two death-domain (DD)-containing TRAIL-Rs. In addition to its limited agonistic capacity, dulanermin has a short in-vivo half-life (5) , and, like other recombinant forms of TRAIL, binds to the nonapoptosis-inducing TRAIL-Rs, TRAIL-R3 (DcR1), TRAIL-R4 (DcR2) and Osteoprotegerin (OPG), which may attenuate the pro-apoptotic activity exerted by its interaction with TRAIL-R1 and/or TRAIL-R2. Consequently, agonistic antibodies to TRAIL-R1 and TRAIL-R2 with a longer half-life and more restricted receptor specificity than recombinant TRAIL were also developed for clinical use (6) . However, despite encouraging preclinical studies (2, 7) very few patients responded to either dulanermin (5, 8) or TRAIL-R1/2-targeting antibodies (9) (10) (11) in clinical trials conducted thus far. This suggests that the current clinical approaches of targeting TRAIL-R1 and TRAIL-R2 should be re-examined before further studies are undertaken in patients.
Interestingly, Fcγ receptors (FcγR) on immune cells were recently shown to be capable of crosslinking antibodies against DD-containing TRAIL-Rs which rendered these antibodies active in killing cancer cells in vivo (12, 13) . We therefore tested whether we could identify conditions under which a clinically used TRAIL-R2-specific antibody, AMG655, which has so far not shown any significant clinical activity, could be rendered active by exploiting this phenomenon. Because the tumour microenvironment in ovarian cancer is rich in FcγR-expressing immune cells (14) and because TRAIL may serve as a treatment for ovarian cancer (6, 15, 16) , we set out to investigate whether FcγR-expressing immune cells in the ovarian cancer microenvironment would enable AMG655-mediated killing of patientderived ovarian cancer cells. Surprisingly, these experiments led us to discover a previously unrecognised synergy between AMG655 and TRAIL in killing primary ovarian cancer cells specifically which, importantly, is independent of the presence of immune cells.
Results and Discussion

Treatment of primary ovarian cancer cells with bortezomib or SMAC mimetics enhances apoptosis induction by iz-TRAIL
We first used iz-TRAIL, a highly active recombinant form of TRAIL which we previously developed for preclinical studies (4), to determine whether primary ovarian cancer cells were TRAIL-sensitive or -resistant and whether proteasome inhibitors or SMAC mimetics enhanced their sensitivity to TRAIL. We obtained primary ovarian cancer cells from chemotherapy-resistant patients (Supplementary Table S1 and Supplementary Figure S1 ) and found that whilst treatment with iz-TRAIL was capable of killing these cells, this was only true for 38% of the cases (Figure 1a ). Co-treatment with the proteasome inhibitor bortezomib/PS-341 (Figure 1b) or the SMAC mimetic compound SM083 (Figure 1c) , however, rendered these cells sensitive to iz-TRAIL-induced apoptosis in 52% and 66% of the cases, respectively. These results confirm those obtained by others (15, 17) , implying that a highly active clinical TRAIL-R agonist could be used to treat ovarian cancer patients, preferably in combination with a proteasome inhibitor or a SMAC mimetic compound.
Primary ascites-derived human CD45-positive cells are inefficient enablers of FcγR-dependent TRAIL-R2-mediated apoptosis
Considering that FcγRs on immune cells were proposed to enable apoptosis induction by TRAIL-R-targeting antibodies by crosslinking them, in conjunction with the fact that the ovarian cancer microenvironment, especially in ascites, often contains high numbers of FcγR-expressing immune cells, we reasoned that TRAIL-R2 antibodies might be an effective treatment for ovarian cancer. We therefore tested the efficacy of the TRAIL-R2-specific antibody AMG655 at killing ovarian cancer cells in the presence of ascites-derived immune cells. We first confirmed the presence of different immune cell subsets and overall FcγR expression on CD45-positive (CD45) immune cells isolated from ovarian cancer ascites (Figure 2a ). Myeloid cells (macrophages and neutrophils) were abundant in ovarian cancer ascites and expressed high levels of CD16 (FcγRIIIA), CD32 (FcγRIIA), and CD64 (FcγRIA) (Figure 2b ). NK cells were found in lower numbers in ovarian cancer ascites and expressed CD16 (FcγRIIIA) (Supplemental Figure S2a) .
To determine the efficiency of FcγR-mediated TRAIL-R2-antibody crosslinking by ascitesderived immune cells and a potential increase in agonistic activity achieved thereby, we employed the highly TRAIL-sensitive PEO4 cell line. However, even at the highest ratio of ten immune cells to one PEO4 cell, the level of AMG655-induced apoptosis was modest (Figure 2c ). The results from individual patients were divided into three groups, low (<10%), medium (>10% and <25%), and high (>25%), dependent on the capacity of their CD45+ FcγR-expressing cells to induce FcγR-dependent TRAIL-R2-mediated apoptosis of PEO4 cells (Supplementary Figure S3) . This allowed the determination of the relative contribution of the different FcγRs and immune cell subsets towards AMG655-mediated crosslinking of TRAIL-R2. Higher expression of FcγRIIIA (CD16) and FcγRIA (CD64) expression and macrophages (within the 10 to 1 ratio treated group) were associated with enhanced AMG655-mediated apoptosis (Figure 2d, e) . Although a polymorphism at FcγRIIA 131H/H versus FcγRIIA 131H/R was reported to enhance TRAIL-R2-mediated apoptosis (12), the polymorphism frequencies were similar between different patient groups (Supplementary Table S3 ). In summary, the efficiency of apoptosis induction by FcγR-crosslinked AMG655 never reached the levels achieved by iz-TRAIL or a non-tagged recombinant form of TRAIL that we synthesised according to known dulanermin specificities which is referred to as Apo2L/TRAIL herein ( Figure 2c ).
Thus, human FcγR-expressing immune cells were unable to enhance anti-TRAIL-R2-induced apoptosis in primary ovarian cancer cells to any significant level (Figure 2f ). Yet, Apo2L/TRAIL and, even more potently, iz-TRAIL were capable of inducing apoptosis in primary ovarian cancer cells, suggesting that recombinant forms of TRAIL are more effective at multimerising TRAIL-R1 and/or TRAIL-R2 and, consequently, at inducing apoptosis than the TRAIL-R2-specific antibody AMG655 in these cancer cells. Although these are in-vitro studies, the ratio of immune to cancer cells that was sufficient to drive FcγR-dependent TRAIL-R2-mediated apoptosis was substantially higher than the most favourable ratios we found in solid deposits of ovarian cancer (Supplementary Figure S4) . We therefore conclude that the concept of enabling TRAIL-R2-mediated apoptosis in cancer cells via FcγR-expressing human immune cells is most likely not viable for the majority of cancers.
AMG655 and Apo2L/TRAIL synergise to potently kill ovarian cancer cells via TRAIL-R2
Based on these results, we hypothesized that the binding of AMG655 to TRAIL-R2 might interfere with the binding of endogenous TRAIL to TRAIL-R2. If true, AMG655 treatment might even be counterproductive by preventing the killing of cancer cells by endogenous TRAIL (18) . Unexpectedly however, when testing this hypothesis, we found that AMG655 did not block, but instead profoundly enhanced the capacity of Apo2L/TRAIL to induce apoptosis in cancer cells. Together, AMG655 and Apo2L/TRAIL were as active in killing ovarian cancer cells as iz-TRAIL (Figure 3a ). AMG655 enhanced Apo2L/TRAIL-induced apoptosis in TRAIL-sensitive and TRAIL-resistant ovarian cancer cell lines treated with or without SMAC mimetics ( Figure 3a) . The activity of iz-TRAIL was not inhibited but, in contrast to Apo2L/TRAIL, also not increased by AMG655 (Figure 3b ). This suggests that there is most likely a maximum proapoptotic agonistic activity that is achievable by TRAIL-R-crosslinking which is reached by both iz-TRAIL alone and the combination of Apo2L/ TRAIL with AMG655. The synergism between AMG655 and Apo2L/TRAIL was observed at concentrations of AMG655 as low as 100 ng/ml (Figure 3c ), which is more than two orders of magnitude below the levels achieved in patients (5, 19) . Importantly, the TRAIL-R2-specific antibody AMG655 we employed here has been used clinically and the nontagged Apo2L/TRAIL form we employed mimics dulanermin which has also already been tested in clinical trials (2, 4) . Hence, this combination represents a highly active TRAIL-R2-agonistic therapy that could be suitable for immediate use in patients.
Intriguingly, the synergy of AMG655 with Apo2L/TRAIL in killing cancer cells was unique amongst three different TRAIL-R1/2-specific antibodies we tested (Figure 3d ), indicating that not all TRAIL-R2-specific antibodies synergise with Apo2L/TRAIL to kill cancer cells. When examining the molecular basis for this specificity, we found that Apo2L/TRAIL significantly reduced the binding of HS201, but not of AMG655, to TRAIL-R2 (Figure 3e ).
Thus, Apo2L/TRAIL and HS201 appear to bind TRAIL-R2 at overlapping epitopes, thereby preventing these two proteins from acting in synergy. AMG655 instead binds TRAIL-R2 at an epitope that does not interfere with the receptor's concomitant interaction with Apo2L/ TRAIL so that both proteins can bind TRAIL-R2 simultaneously, resulting in enhanced TRAIL-R2 crosslinking and apoptosis-inducing capacity. In line with this, the combination of Apo2L/TRAIL with AMG655, but not with HS201, was able to trigger effective DISCmediated caspase-8 activation with subsequent Bid cleavage (Figure 3f ). We hypothesised that the effect of AMG655 on Apo2L/TRAIL-induced apoptosis could be mediated by concomitant binding to TRAIL-R2 which would lead to enhanced multimerisation of TRAIL-R2 and, consequently, increased formation of the TRAIL death-inducing signalling complex (DISC) (20) . In line with this hypothesis, AMG655 significantly enhanced Apo2L/ TRAIL-mediated recruitment of FADD, Caspase-8 and cFLIP and, hence, TRAIL DISC formation (Figure 3g ). This indicates that the synergistic apoptosis-inducing activity of AMG655 and Apo2L/TRAIL is due to increased TRAIL DISC formation as a consequence of enhanced TRAIL-R2 crosslinking. Furthermore, synergistic cell death induction by AMG655-Apo2L/TRAIL was blocked by caspase inhibition (Figure 3h ) but not by inhibition of JNK (21) (Supplementary Figure S6) , indicating that the AMG655-Apo2L/ TRAIL combination induces apoptotic cell death (2).
It was recently shown that some TRAIL-resistant ovarian cancer cell lines require activation of the mitochondrial pathway for TRAIL-induced apoptosis (21) . We therefore next investigated whether the synergistic effect of AMG655 and Apo2L/TRAIL requires activation of the mitochondrial apoptotic pathway by using a genetically defined system of isogenic HCT-116 colon carcinoma cell lines which are either wild-type (HCT116-WT) or deficient for Bax and Bak (HCT116-Bax/Bak-dko) (Supplementary Figure S7a) . HCT116-WT and HCT116-Bax/Bak-dko cells both expressed similar levels of TRAIL-R1 and TRAIL-R2 on their surface (Supplementary Figure S7b) . Whereas HCT116-WT cells were sensitive to AMG655-Apo2L/TRAIL, HCT116-Bax/Bak-dko cells were resistant (Supplementary Figure S7c) , indicating that the AMG655-Apo2L/TRAIL combination cannot overcome resistance to TRAIL-induced apoptosis that is due to a block in the apoptosis pathway at the mitochondrial level. However, addition of bortezomib re-sensitised HCT116-Bax/Bak-dko cells to AMG655-Apo2L/TRAIL (Supplementary Figure S7c) , indicating that the mitochondrial block to the novel TRAIL-R-agonist combination can be overcome by bortezomib, as previously shown for other TRAIL-R agonists (22) .
We next investigated whether the synergy between AMG655 and Apo2L/TRAIL was mediated solely by TRAIL-R2 or whether there was a contribution of TRAIL-R1. To do so, we performed transient knockdowns of TRAIL-R1 and TRAIL-R2 since these were both expressed on PEO4 cells (Supplementary Figure S8a) . We found that suppression of TRAIL-R2 completely reversed the synergistic effect of AMG655 and Apo2L/TRAIL treatment on cell death (Supplementary Figure S8, b and c) , whereas TRAIL-R1 knockdown only resulted in a minor reduction which was most likely attributable to co-suppression of TRAIL-R2 by TRAIL-R1 knockdown (Supplementary Figure S8b and c) . These data show that the synergy of AMG655 with Apo2L/TRAIL in inducing apoptosis depends on TRAIL-R2.
AMG655 and Apo2L/TRAIL synergise to kill primary ovarian cancer cells but not primary human hepatocytes
We next investigated whether AMG655 could also synergise with Apo2L/TRAIL in killing primary ovarian cancer cells. Indeed, the combination of AMG655 with Apo2L/TRAIL was as active as iz-TRAIL in killing primary ovarian cancer cells (Figure 4a ). When used in combination with SM083, we observed that the AMG655-Apo2L/TRAIL combination was again as active as iz-TRAIL when combined with SM083 in killing primary ovarian cancer cells (Figure 4b) . Thus, the combination of Apo2L/TRAIL with AMG655 can kill patientderived primary ovarian cancer cells, and further combination with a SMAC mimetic drug, and/or possibly other TRAIL-sensitising agents, may hold great therapeutic promise for ovarian cancer.
In mice, highly active forms of TRAIL and SMAC mimetic compounds can be combined without causing overt toxicity (23, 24) . Given that AMG655 binds to human TRAIL-R2 but not to the only murine DD-containing TRAIL-R (mTRAIL-R/mDR5), the potential toxicities of therapeutic combinations of AMG655 cannot be evaluated in mouse models. Also, such xenograft models (2, 7) are not predictive of the potential clinical efficacy of AMG655 and dulanermin. Because of these considerations and previous concerns regarding the potential liver toxicity of TRAIL (3, 4, 25, 26), we next examined whether primary human hepatocytes were sensitive to apoptosis induction by the AMG655-Apo2L/TRAIL combination, either alone or in the presence of SM083 or bortezomib. As control we used CD95L, a potent killer of primary human hepatocytes (4). We found that treatment with the combination of Apo2L/TRAIL and AMG655 did not induce any significant changes in cellular morphology (Figure 4c ), loss of cell viability (Figure 4d ), or increase in the death of primary human hepatocytes (Figure 4e) . None of the AMG655-and Apo2L/TRAILcomprising treatments resulted in a significant increase in liver enzyme production ( Figure  4f ). These results are in line with our previous findings regarding the effects of highly active recombinant forms of TRAIL on primary human hepatocytes (4). Importantly, also further combination with SM083 or bortezomib did not induce a significant decrease in the viability of primary human hepatocytes (Figure 4d) . Thus, combining AMG655 and Apo2L/TRAIL, with or without SM083 or bortezomib, does not kill primary human hepatocytes.
Taken together, on the basis of our findings we propose that it should be possible to overcome the limited efficacy of currently clinically employed TRAIL-R agonists, in a cancer-cell-specific manner, either by combining two of them, AMG655 and dulanermin, or by employing single-agent highly active forms of recombinant TRAIL (1, 4, 27) , possibly in combination with SMAC mimetics, proteasome inhibitors or other potent TRAIL apoptosis sensitisers (28). We anticipate that our findings will contribute to the introduction of a highly active TRAIL-R-agonistic therapy into the cancer clinic.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material. Treatment of primary ovarian cancer cells with bortezomib or SMAC mimetics leads to enhanced iz-TRAIL-induced cell death. Primary ovarian cancer cells were isolated from 18 patients with advanced ovarian cancer (Supplementary Table S1 and Supplementary Figure  S1 ). (a) Primary ovarian cancer cells were cultured in 50% RPMI and 50% ascites which was 0.22 μm sterile filtered and supplemented with 1% penicillin/streptomycin/gentamycin/ glutamine at 37°C in a humidified incubator with 5% CO 2 (e) PHH death was determined 24 hours after onset of treatment as in (a) by measuring release of soluble keratin 18 (K18) using the M65® ELISA (Peviva) according to the manufacturer's instructions (n=3 ± S.D.). (f) Presence of the liver enzyme AST in PHH culture supernatants was measured 24 hours after onset of treatment. Release of intracellular hepatocyte-specific AST liver enzymes was measured using the Reflovet plus instrument
